Comparative Pharmacology
Head-to-head clinical analysis: MACROTEC versus ULTRATAG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACROTEC versus ULTRATAG.
MACROTEC vs ULTRATAG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not applicable for diagnostic use.
Inhibits hepatic glucose production by activating AMP-activated protein kinase (AMPK) and reduces intestinal glucose absorption; also improves insulin sensitivity.
5 mCi (185 MBq) intravenously as a single dose for lung perfusion imaging.
NOT FOUND
None Documented
None Documented
6 hours; prolonged in renal impairment (up to 30 hours in ESRD)
Terminal elimination half-life is 12-15 hours (mean 13.5 h); clinically significant for twice-daily dosing in hepatic impairment or drug interactions.
Renal: 95% as unchanged drug; biliary/fecal: <5% as metabolites
Primarily renal excretion of unchanged drug (60-70%); biliary excretion accounts for 20-25%; fecal elimination <10%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical